HAO1 and neoplasm: These systems leverage GOX's unique catalytic activity to achieve dual therapeutic benefits: (1) tumor-selective drug release through pH-responsive mechanisms, and (2) reversal of multi-drug resistance (MDR) via ATP depletion-mediated inhibition of efflux pumps [83,84].